situ hibridizasyon yöntemi i - Çukurova Üniversitesi

100. Miller AJ, Mihm MC Jr. Melanoma. N. Engl. J. Med. 2006; 355: 51–65.
101. Peysonnaux C, Eychenne A, The Raf/MEK/ERK pathway: new concept of activation. Biol cell
2001; 93: 53-26,
102. Giehl K, Oncogenic ras in tumour progression and metastasis. Biol Chem, 2005; 386: 193-205.
103. Ball NJ et al: Ras mutations in human melanoma: A marker of malignant progression. J Invest
Dermatol 1994; 102:285-290.
104. Van’t Veer LJ et al: N-ras mutations in human cutaneous melanoma from sun-exposed body
sites. Mol Cell Biol 1989; 9:3114-3116.
105. Albino AP et al:Analysis of ras oncogenes in malignant melanoma and precursor lesions:
Correlation of point mutations with differentiation phenotype. Oncogene 1989; 4: 1363-1374
106. Hocker T, Tsao H Ultraviolet radiation and melanoma: a systematic review and analysis of
reported sequence variants. Hum Mutat 2007; 28:578–88
107. Davies H et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54
108. Brose MS, Volpe P, Feldman M, B-RAF ve RAS mutations in human lung cancer and
melanoma. Cancer Res 2002; 62: 6997-7000,
109. Caduff RF, Svoboda-Newmann SM, Ferguson AW, Johnston CM. Comparison of Ki-RAS and
p53 immünoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Patho.
1999; 23: 323-8,
110. Pollock PM, Harper UL, High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-
20,
111. Van Raamsdonk CD, Bezrookove V, Green G et al. Frequent somatic mutations of GNAQ in
uveal melanoma and blue naevi. Nature 2009; 457: 599–602.
112. Thomas L. AT AL. Melanoma Genetics and Therapeutic Approaches in the 21st Century:
Moving from the Benchside to the Bedside Journal of Investigative Dermatology, 2008; 128,
2575–2595
113. Kumar V, Abbas A.K, Fausto N. Robbins and Cotran Pathologic Basis of Disease 7th ed.
Elsevier Saunders, 2005: ISBN 0-8089-2302-1
114. Sherr CJ: The ins and outs of RB: Coupling gene expression to the cell cycle clock. Trends Cell
Biol, 1994; 4:15-18
99